This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
3 Small Biotechs Provide Coronavirus Drug Development Updates
by Kinjel Shah
Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.
The Zacks Analyst Blog Highlights: Co-Diagnostics, GenMark Diagnostics, OPKO Health and Inovio Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Co-Diagnostics, GenMark Diagnostics, OPKO Health and Inovio Pharmaceuticals
4 Stocks to Gain the Most From the Coronavirus Outbreak
by Nilanjan Banerjee
It is worthwhile to keep an eye on stocks of companies that are engaged in the prevention, diagnosis and treatment of the disease.
The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Vir Biotechnology and Alnylam Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Vir Biotechnology and Alnylam Pharmaceuticals
Will Inovio Pharmaceuticals (INO) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Inovio (INO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
House Okays $8 Billion Funds to Combat COVID-19: 3 Winners
by Manaswita Ghosh Dutta
U.S. lawmakers' deal to find a vaccine for tackling the coronavirus stands to benefit the healthcare industry.
Inovio Surges on Expedited Timeline for Coronavirus Vaccine
by Zacks Equity Research
Inovio (INO) to initiate human clinical studies on INO-4800, its DNA vaccine, this April, for the treatment of the deadly coronavirus. The stock price shoots up.
5 Drug Makers to Gain From Coronavirus Outbreak
by Zacks Equity Research
Drug makers globally are working on developing therapies and vaccines for coronavirus. Here are five stocks that are currently in focus.
4 Top Stocks to Win Big From the Coronavirus Pandemic (Revised)
by Tirthankar Chakraborty
Professional money managers are looking to buy stocks that act as a hedge against coronavirus threat, or those that simply benefits from the particular event.
The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Co-Diagnostics and Apple
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Inovio Pharmaceuticals, Co-Diagnostics and Apple
5 Biotechs That Escaped the Coronavirus Onslaught Last Week
by Kinjel Shah
Here we discuss 5 biotech stocks that outperformed the industry amid the U.S. market slump.
4 Top Stocks to Win Big From the Coronavirus Pandemic
by Tirthankar Chakraborty
Professional money managers are looking to buy stocks that act as a hedge against coronavirus threat, or those that simply benefits from the particular event.
Inovio Pharmaceuticals (INO) Stock Moves -1.84%: What You Should Know
by Zacks Equity Research
In the latest trading session, Inovio Pharmaceuticals (INO) closed at $4.28, marking a -1.84% move from the previous day.
The Zacks Analyst Blog Highlights: Moderna, Vaxart, Inovio Pharmaceuticals and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Vaxart, Inovio Pharmaceuticals and Novavax
4 Healthcare Stocks to Gain as Coronavirus Threat Looms Large
by Zacks Equity Research
Healthcare companies are trying to find a cure and contain the coronavirus outbreak. This keeps the industry in focus
Inovio Gets FDA Nod to Begin Study on INO-3107, Stock Gains
by Zacks Equity Research
The FDA accepts Inovio's (INO) IND application for INO-3107 to initiate a phase I/II study for the treatment of recurrent respiratory papillomatosis, a rare disease caused by HPV. Stock up.
Is Inovio Pharmaceuticals (INO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (INO) Outperforming Other Medical Stocks This Year?
Vaxart (VXRT) to Make Vaccines to Check Coronavirus, Stock Up
by Zacks Equity Research
Vaxart (VXRT) begins a program to develop a vaccine candidate to counter the new coronavirus infection. Shares jump.
Company News for Jan 31, 2020
by Zacks Equity Research
Companies In The News Are: BGG, INO, MDLZ, MGEN
Coronavirus: How Fast to 100,000 Infected?
by Kevin Cook
The current geometric rate of transmission implies that over 100,000 people could be infected by early February.
Coronavirus: Epidemic or Pandemic?
by Kevin Cook
The current geometric rate of transmission implies that over 100,000 people could be infected by early February.
Coronavirus Spooks Global Markets: Winners and Losers
by Zacks Equity Research
So far, 18 fatalities and more than 600 are affected by coronavirus in China and the virus is spreading across the boundary, spooking investors.
CEPI Grant, Government Aid Drive Coronavirus Focused Biotechs
by Indrajit Bandyopadhyay
Several public and private organizations are coming forward to develop vaccines for the new coronavirus by funding developmental programs.
Implied Volatility Surging for Inovio (INO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.
Merck's Ebola Vaccine Ervebo Gets Approval in United States
by Zacks Equity Research
FDA grants approval to Merck's (MRK) Ervebo vaccine for active immunization of individuals 18 years and above to protect against Ebola virus disease caused by Zaire Ebola virus.